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ABSTRACT  
Vitamin D plays a key role in mineral homeostasis, in which its main biological effect is to 
maintain adequate serum calcium levels. The systemic deficiency of either 1,25D or its 
receptor (VDR) is associated with bone alterations such as rickets and osteomalacia. This 
review summarizes the evidence supporting a direct effect of vit D-VDR on bone cells. 
The presence of vit D-hydroxylases as well as VDR in several cell types, supports an 
autocrine / paracrine role for vitamin D. Bone-derived cells also express VDR, and thus it 
is currently hypothesized that 1,25(OH)2 vitamin D (1,25D) directly controls specific 
aspects of bone and mineral homeostasis. Several forms of vitamin D have been shown to 
induce specific and direct effects on different cells from bone and cartilage, such as 
chondrocytes, osteoblasts, osteocytes, osteoclasts and bone marrow stromal cells. Both 
catabolic and anabolic effects of vitamin D have been demonstrated in bone, mediated by 
different signal transduction mechanisms. In addition to the classic VDR mediated actions, 
non-classic and rapid effects of vitamin D have also been demonstrated in bone cells.  
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Vitamin D (vit D) plays a key role in mineral homeostasis and its main biological effect is 
to maintain serum calcium (Ca) levels within the normal range [1]. It regulates intestinal 
calcium and phosphate (P) transport, maintains circulating calcium and phosphate levels 
that can support bone formation, exerts potent effects on cell growth and differentiation, 
and can modulate the immune response. Classically, vit D interacts in an endocrine manner 
with parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), thus regulating 
Ca and P levels. The presence of several vit D-hydroxylases and the receptor (VDR) in 
several cell types supports an autocrine/paracrine role for vit D.  
Several clinical situations are associated with vit D deficiency, such as ageing and chronic 
kidney disease. They are characterized by impaired Ca absorption, secondary 
hyperparathyroidism, and bone resorption and bone loss. These observations suggest an 
important role for vit D in bone metabolism and Ca/P homeostasis. 




Synthesis and metabolism of vitamin D 
 
Vit D is obtained in the skin by ultraviolet (UV) irradiation of 7-dehydrocholesterol, which 
thus opens its B ring to form pre-vitamin D (Figure 1) [2]. Pre-vit D can then isomerize to 
vit D (cholecalciferol or D3), or with continued UV irradiation can form tachysterol and 
lumisterol. Vit D is also found in small quantities in the diet in the form of ergocalciferol 
(D2) or cholecalciferol (D3), which differ in their side chains and thus show differences 
both in their affinity for vit D-binding protein (DBP) and in their subsequent metabolism. 
The liver and other organs hydroxylate vit D (either synthesized by the skin or of dietary 
origin), to 25-OH vit D (25D), the principal and major circulating form of vit D [2,3]. The 
enzyme responsible for this modification is the cytochrome P450 (CYP)-dependent 25-
hydroxylase (CYP2R1) [4]. 
25D is then metabolized to 1,25(OH)2 vit D (1,25D) principally in the renal proximal 
tubule by an enzyme identified as 1α-hydroxylase (CYP27B1). 1,25D is the main 
hormonal form of vitamin D, and is responsible for most of its biological actions. 
Production of 1,25D by the kidney is strictly dependent on renal 1α-hydroxylase activity. 
This enzyme is regulated by a negative feedback of 1,25D, by PTH as a signal of Ca status 
(PTH is secreted to stimulate CYP27B1 when serum Ca levels are low) and by FGF23 as a 
signal of P homeostasis (FGF23 is produced in the bone in response to elevated P levels 
and inhibits CYP27B1 synthesis) [4]. 1,25D is a hormone that plays a critical role in 
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Figure 1. Vitamin D metabolism and regulation. Cholecalciferol (vit D3) is synthesized from 7-
dehydrocholesterol in the skin by UV exposure. Vit D can also be obtained from diet in the form of 
ergocalciferol (vit D2) and vit D3. Both are transformed to calcidiol (25(OH)D or 25D) by cytochrome 
enzymes CYP2R1 and CYP27A1. Then, 25D is hydroxylated in the kidney and in other organs such as bone, 
by the CYP27B1/1α-hydroxylase. The renal enzyme is regulated by PTH, Ca and P levels, FGF23 and 




Other cells such as keratinocytes, parathyroid principal cells, enterocytes, macrophages, 
various bone cells and chondrocytes also express 1α-hydroxylase. This extra-renal 
production of 1,25D is regulated by different mechanisms: it can be stimulated by 
cytokines such as tumor necrosis factor-α, interferon-γ, and interleukin (IL)-1β [5]. 
25D and 1,25D can be further hydroxylated by induction of a 24-hydroxylase (CYP24A1) 
to form 24,25(OH)2 vit D (24,25D) and 1,24,25(OH)3 vit D (1,24,25D), respectively. This 
is generally considered the first step in the catabolism of the active metabolites. However, 
24,25D and 1,24,25D may have their own biological actions; in particular, 24,25D could 
be the principal metabolite regulating chondrocyte function in the resting zone [2]. 
CYP24A1 is induced by 1,25D, and thus constitutes an important feedback mechanism to 
prevent vit D toxicity. Vit D metabolites are transported in blood bound to DBP and 
albumin, with very little vit D circulating in a free form. Individuals with liver, intestinal, 
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or renal diseases resulting in low levels of these transport proteins, may have low total 
levels of vit D metabolites but they are not vit D deficient; in fact, free vit D concentrations 
may actually be normal [6]. 
 
 
Vitamin D metabolites and their effects on different bone cells 
 
The systemic deficiency of 1,25D activity or of its receptor (VDR) is associated with bone 
defects such as rickets and osteomalacia. The observation that these bone abnormalities 
can be rescued by a high-Ca diet or by reintroducing VDR in the small intestine indicates 
that a critical role of 1,25D is to enhance intestinal Ca absorption. Although 1,25D 
signaling in bone cells is not a prerequisite for bone development and homeostasis when 
intestinal Ca transport is guaranteed, multiple bone cells express the VDR and it is 
hypothesized that through its action on these cells 1,25D directly controls specific aspects 
of bone and mineral homeostasis [1]. 
 
 
Vitamin D action on chondrocytes 
 
The skeletal system contains mainly cartilage and bone, formed by chondrocytes and 
osteoblasts, respectively. Both cells are derived from mesenchymal progenitor cells. Bone 
tissue is constantly being renewed by a precise coupling of resorption, mediated by 
osteoclasts, and formation, in a process that has been termed remodeling. The quality of 
the bone is maintained by the action of osteocytes, a network of sensory cells mediating the 
effects of mechanical loading. 
The major skeletal manifestation of a systemic loss of 1,25D signaling is rickets, 
characterized by an expansion and widening of the growth plate with marked 
disorganization of its associated chondrocytes. These growth plate abnormalities most 
likely result from hypophosphatemia, since several hypophosphatemic conditions result in 
similar growth plate abnormalities and normal phosphorus levels are required for growth 
plate maturation [7]. 
1,25D signaling in chondrocytes appears to be redundant when mineral homeostasis is not 
manifestly disturbed, but is critical to prevent the growth plate abnormalities of rickets 
when hypophosphatemia is present [1].	VDR expressed in chondrocytes has an important 
paracrine function that is directed at fine-tuning fetal and early post natal bone 
development. Indeed, chondrocyte-specific VDR inactivation in mice shows that 1,25D 
controls vascular invasion and osteoclast formation in the primary ossification center by 
increasing the angiogenic cytokine VEGF (vascular endothelial growth factor) and the pro-
osteoclastic protein RANKL [receptor activator of nuclear factor-ΚΒ (RANK) ligand] [8]. 
The 1,25D and 24,25D are required for optimal endochondral bone formation [2]. Growth 
cartilage chondrocytes respond primarily to 1,25D, whereas resting zone cells respond 
primarily to 24,25D [9]. It seems that certain actions of 1,25D and 24,25D in chondrocytes 
do not need the VDR and are thus nongenomic [2]. 
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Vitamin D effects on osteoblasts 
 
The bone phenotype of hypocalcemic VDR-null mice is characterized by growth plate 
defects, as well as by unbalanced bone remodeling and osteomalacia. Increased numbers of 
osteoblasts line the bone surfaces but mineral apposition is impaired. As a result, although 
total bone mass is increased, this is due to an excess in unmineralized bone matrix [1]. 
Osteocytes and osteoblasts respond to 1,25D via VDR, inducing the expression and release 
of FGF23 to control phosphatemia. 1,25D also repress CYP27B1 and induce CYP24A1 in 
these cells, in order to reduce 1,25D levels by feedback mechanisms [3]. 
Although defects in 1,25D signaling can affect osteoblastic differentiation and bone 
formation, this is predominantly due to its role in the intestine. However, in vitro 
experiments have also provided evidence for the direct regulation of osteoblast 
differentiation by VDR action, in a species-dependent manner. In human pre-osteoblasts, 
1,25D induces differentiation [10]. These effects are biphasic in rat osteoblastic cells: 
1,25D enhances differentiation at late osteoblastic stages and inhibits differentiation in 
early pre-osteoblasts. The differentiation of mouse osteoblastic cells is inhibited at all 
times by 1,25D treatment, independently of the differentiation stage [1]. 
Normalizing serum Ca and P levels completely rescues the bone phenotype of VDR-null 
mice, indicating that their mineralization defects are due to an insufficient supply of these 
ions to the bone matrix, caused in turn by 1,25D deficiency. However, hypervitaminosis D 
in rats is also often associated with bone mineralization defects such as bone loss and 
abundant unmineralized bone matrix [1]. 
Osteoblasts are functionally associated with specific niches of the bone microenvironment 
in which hematopoietic stem cells (HSC) reside. This fact could indicate that VDR 
signaling, via its effect on extracellular Ca, may be involved in promoting retention of 
HSC (thus favoring hematopoiesis) in the bone marrow. Other reports demonstrate that 
VDR signaling in osteoblasts, and not extracellular Ca, is required to suppress the 
osteoblastic niche and induce mobilization of HSC in the circulation, in response to 
adrenergic stimulation [11]. The HSC mobilization is hampered in VDR-null mice, even 
on a rescue diet.  
In summary, although it is accepted that 1,25D affects the skeleton mainly via its actions 
on the intestine and the regulation of mineral homeostasis, direct effects of 1,25D are also 




Vitamin D action in osteoclasts 
 
Using an in vitro organ culture system, both 1,25D and 25D have been shown to increase 
the release of Ca from prelabeled bone into the culture medium. In these experiments, 
1,25D was found to be 80 times more potent than 25D, suggesting that 1,25D is the active 
metabolite stimulating bone mineral mobilization [5]. An efficient mouse co-culture 
system to generate osteoclasts has been established with calvaria-derived osteoblasts and 
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spleen cells. In this co-culture system, 1,25D induces the formation of multinucleated 
osteoclasts. Cell-cell contact between spleen cells and osteoblastic cells, which express 
VDR, appears to be important for both the formation and activation of osteoclasts. 1,25D 
regulates osteoclast differentiation indirectly; by increasing the osteoblastic expression of 
the osteoclastogenic factor RANKL while reducing the expression of the anti-osteoclastic 
protein osteoprotegerin (OPG) [12]. 
VDR-deficient osteoblasts result in increased bone mass. This was reported by Yamamoto 
et al [13], who noted that even heterozygote ablation of VDR induced an increase of bone 
mass, due more to a down-regulation of osteoclast activity rather than an increase in bone 
formation. Further analysis indicated that VDR in osteoblasts could act as a negative 
regulator of bone mass through stimulation of RANKL-induced osteoclastogenesis [14]. 
 
 
Vitamin D mechanism of action on bone cells 
 
The effects and mechanisms of action of vit D on bone cells will depend on several factors: 
(a) ability to metabolize and synthesise 1,25D, (b) expression of 1α-hydroxylase, (c) VDR 
expression, and (d) presence of co-activator/repressor proteins that regulate gene 
transcription. 
Vit D action requires binding of the active form of vit D, 1,25D, to its specific receptor 
VDR, thus initiating biological responses [15]. Although 25D can also activate VDR, it 
affinity for this receptor is 50-fold less than that of 1,25D [16]. The vit D-VDR complex 
then interacts with a co-receptor, the retinoid X receptor (RXR), and this heterodimer in 
turn will regulate the transcription of different genes. This mechanism is mediated by 
different vit D response elements (VDREs) present in diverse gene sequences. In addition, 
the regulation (activation or repression) of transcription is affected in part by the 
interaction of the ligand-VDR-RXR complex with co-activator or co-repressor proteins 
that will regulate the chromatin structure of target genes.  
Transcriptional regulation has generally been believed to occur near the transcriptional 
start site of each gene. However, the use of new tools such as chromatin 
immunoprecipitation techniques (ChIP-seq) and gene scanning methodologies have 
provided new insights into the mechanism of action of vit D [17]. It has been suggested 
that VDR-transcription factor interaction depends on the specific target cells. In the case of 
the pre-osteoblastic MC3T3E1 cell line, distal transcriptional control has been shown to 
regulate most of vit D-mediated gene transcription [18]. Molecular studies have also 
suggested that the regulation of gene transcription depends on a variety of different 
transcription factors that regulate multiple signalling pathways. For instance, vit D can 
increase the LRP5 co-receptor gene of the Wnt pathway and also directly suppress the 
activity of β-catenin signaling molecule [19]. Interestingly, activation of the Wnt/β-catenin 
pathway is associated with increased bone formation. 
In addition, evidence has been presented of a fast non-transcriptional mechanism for vit D 
action in skeletal muscle and osteoblastic cells [20]. These actions involve an increase in 
intracellular Ca and stimulation of different kinases related to signal transduction 
pathways. Both voltage-dependent and capacitive Ca entry channels mediate this increase 
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in intracellular Ca. It has been suggested that the presence of different plasma membrane 
receptors, or even VDR, could mediate these rapid, nongenomic actions of vit D [21]. 
Various bone cells and their progenitors have been found to possess the molecular 
machinery necessary to respond to -and metabolize- vit D [12]. They express 1α-
hydroxylase, and regulate its expression depending on the levels of 1,25D. Osteoblasts also 
coordinately regulate the expression of VDR mRNA levels. 
The consequences of 1,25D-VDR signalling on bone cells largely depend on Ca balance 
[22]. Thus, direct or indirect effects of 1,25D on bone will be compromised if necessary, in 
order to maintain normal serum Ca levels. Under a positive Ca balance, 1,25D will 
stimulate intestinal Ca absorption, indirectly affecting bone homeostasis by ensuring 
supply of Ca to bones. However, in the presence of a negative Ca balance (such as in 
dietary calcium restriction or if there is defective intestinal VDR activity), 1,25D-VDR 
signalling can directly enhance bone resorption and impair osteoid mineralization.  
In osteoblastic cell cultures, 1,25D has been shown to play either catabolic or anabolic 
roles on differentiation and mineralization. The specific effect induced by vit D depends on 
the degree of maturation of the osteoblastic cells. 
In human bone marrow stromal cells (hMSCs), 1,25D promotes their osteoblastic 
differentiation [23]. Osteoblastogenesis is also stimulated by 25D, an effect that depends 
on its conversion to 1,25D by the action of 1α-hydroxylase expressed by these cells. Other 
bone cells such as osteoblasts and osteoclasts also express this hydroxylase, supporting an 
autocrine/paracrine action of vit D in the bone microenvironment. 1,25D and 25D show 
VDR-mediated anti-proliferative and pro-differentiation effects in hMSCs, which are 
associated with a stimulation of alkaline phosphatase (ALP) gene expression and activity. 
In vitro treatment with 25D up-regulates CYP27B1/1α-hydroxylase and IGF-I in hMSCs. 
IGF-I also up-regulates CY27B1 expression and stimulates osteoblast differentiation 
(Table 1).  
Human primary osteoblasts also respond to 1,25D and 25D, inhibiting their proliferation 
and stimulating their differentiation [24]. These cells express CYP27B1/1α-hydroxylase 
and CYP24/24- hydroxylase, thus possessing the capacity to produce 1,25D and 24,25D 
respectively. In the presence of 24,25D, they enhance mRNA levels of differentiation 
genes, suggesting that other forms of vit D besides 1,25D may affect osteoblastic 
functions. However, the physiological relevance of these findings needs further research to 
be established. 
Other VDR signals are involved in the anabolic effects of vit D. For instance in human 
trabecular bone cells, 1,25D increases the gene expression of bone matrix proteins such as 
osteocalcin and bone sialoprotein-1, thus enhancing osteoblastic differentiation and 
mineralization [15]. In addition, the 1,25D-VDR axis increases the expression of low-
density lipoprotein receptor-related protein (LRP5) and upregulates the Wnt pathway in 
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Table 1. Anabolic effects induced by vitamin D on bone cells 
 
 
Signal Anabolic Effects 
↑ IGF-I Osteoblastogenesis 
↑ ALP Osteoblastic differentiation 
↑ Osteopontin Osteoid mineralization 
↑ LRP5 Bone formation 
 
 
Under a negative Ca balance or high vit D levels, 1,25D promotes bone resorption, (Table 
2). This effect, that has been demonstrated in animals as well as in vitro in cell culture 
systems [15], is mediated by an increase in RANKL and a decrease of the soluble RANKL 
decoy receptor OPG by osteoblasts and osteocytes [26]. In addition, 1,25D can indirectly 
inhibit bone formation by stimulation of FGF23 release from osteocytes. Synthesis of 
1,25D in the kidney is later repressed by a feedback loop that involves FGF23. In 
osteoblastic cell lines, 1,25D has also been reported to inhibit the master osteoblastic 
transcription factor Runx2, thus potentially reducing their bone forming capacity. 
 
 
Table 2. Catabolic effects induced by vitamin D on bone cells 
 
 
Signal Catabolic Effects 
↑ RANKL Osteoclastogenesis - ↑ Bone resorption 
↓ Osteoprotegerin Osteoblastic differentiation 
↑ FGF23 ↓ Mineralization 
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Conclusion 
 
The primary role of vit D is to stimulate intestinal Ca and P absorption, ions that are 
required for bone formation and mineralization. In the context of normal circulating Ca and 
P levels, these effects on bone can largely be achieved without any direct effects of vit D 
metabolites on bone cells. But there is evidence that the Vit D–VDR system can induce 
direct effects on mature osteoblasts, chondrocytes, osteoclasts and bone marrow stromal 
cells. The Vit D–VDR system can have different functional roles on these cells, depending 
on the stage of differentiation/maturity of the osteoblastic lineage cells, as well as on the 
sufficiency of circulating Ca and/or P levels. Vitamin D metabolites can be catabolic, 
inducing bone resorption and decreasing mineral deposition so as to increase circulating Ca 
levels if there is a deficiency of this ion, as well as to facilitate bone balance when mineral 
supply is sufficient. 
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